Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
uniQure makes one-time gene therapies that fix the root cause of rare diseases by delivering a working copy of a broken gene.
uniQure is a gene therapy company. It focuses on rare diseases that have few or no good treatments. The idea is simple: if a person is missing or has a broken gene, you deliver a working copy of that gene into their cells, and the body starts making the protein it was missing. Think of it as replacing a missing page in an instruction manual so the factory can build the product again. The company makes money mainly by selling its approved therapy and by partnering with larger drugmakers who pay upfront fees, research funding, and future payments if milestones are hit and products reach the market.
Its flagship product is Hemgenix, a one-time treatment for hemophilia B, a bleeding disorder. Hemgenix is approved and sold in the US and Europe, and it brings in product revenue, though adoption has been slow because it is expensive and doctors and payers are still figuring out how to use it. The company also has a pipeline of experimental gene therapies for brain diseases like Huntington's disease and ALS, plus partnerships with big pharma companies. Historically, uniQure started as a small Dutch biotech and became the first company to win approval for a gene therapy in Europe, though that early product was later sold off. Today it is essentially a clinical-stage and early-commercial biotech: it spends heavily on research and trials, has no profits, and funds itself through partnerships, cash reserves, and occasional stock sales. The big question for investors is whether Hemgenix sales ramp up and whether its pipeline programs succeed in trials, because gene therapy is high-risk, high-reward, and each success or failure moves the stock sharply.
Saved answer · last researched 11 Oct 2026